A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Single-Dose or Open-Label Multiple-Dose Study of KHK4083 in Healthy Adults and Subjects With Ulcerative Colitis
Latest Information Update: 10 Feb 2022
At a glance
- Drugs Rocatinlimab (Primary) ; Rocatinlimab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 20 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.